Superluminal Medicines

Accelerating new possibilities in drug discovery and development

Business Model
Other
Last Round
Series A
Rounds
2

About

Superluminal Medicines is a Boston-based generative biology and chemistry company revolutionizing drug discovery with its Hyperloop™ Platform. This platform integrates cutting-edge structure-based drug discovery, AI-powered computational methods, and experimental validation to develop small molecule therapeutics targeting GPCRs for cardiometabolic diseases. Recently, they announced a collaboration with Eli Lilly potentially worth up to $1.3 billion.

Summary

Superluminal Medicines is a Life Sciences company based in Boston, United States. Investors include RA Capital Management, Insight Partners and Catalio Capital Management.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A

Sign up to see all 2 rounds

Series A through Seed — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Superluminal Medicines on Indexed.vc
<a href="https://indexed.vc/companies/superluminal-medicines"><img src="https://indexed.vc/api/badge/company/superluminal-medicines" alt="Superluminal Medicines on Indexed.vc" width="260" height="76" /></a>